Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | HRH2 | P25021 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 7/20 | 0.36 |
| ▸ | DRD4 | P21917 | 5/20 | 0.36 |
| ▸ | DRD3 | P35462 | 5/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.36 |
| ▸ | ITGAV | P06756 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7075914 | 0.97 | CA12 (0.39) | CA12CA1CA2CA9HRH2 | |
| Trifluoroacetic Acid SCHEMBL7075230 | 0.94 | AOC3 (0.36) | CA12CA1CA2CA9DRD2 | |
| Trifluoroacetic Acid SCHEMBL7073057 | 0.88 | DRD2 (0.36) | DRD2DRD4DRD3ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7075140 | 0.88 | ITGB3 (0.36) | DRD2DRD4DRD3ITGB3ITGA2B | |
| SCHEMBL7079103 | 0.87 | HTT (0.40) | DRD2DRD4DRD3MAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL7076491 | 0.86 | ITGB3 (0.35) | DRD2ITGB3ITGA2BITGAV | |
| SCHEMBL7076695 | 0.84 | ITGB3 (0.44) | ITGB3ITGA2BITGAVMAOAMAOB | |
| SCHEMBL7079693 | 0.81 | DRD2 (0.42) | DRD2DRD4DRD3ITGB3ITGA2B | |
| SCHEMBL7073100 | 0.81 | ITGB3 (0.43) | ITGB3ITGA2BITGAVMAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL7075182 | 0.81 | HTT (0.34) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | CA12 4002/4885CA1 2574/4885CA2 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.